Revvity (RVTY) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $1.18 per share a year ago.
Revvity cut its 2024 revenue forecast as reduced biotech spending and a strong dollar weigh on demand for its tools and services used in drug development.
RVTY third-quarter results are likely to reflect decent performance in the Diagnostics segment, while the Life Sciences segment is likely to face continued challenges in China.
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RVTY introduces Transcribe AI that digitizes handwritten test request forms, improving workflow speed and reducing manual data entry errors.
Revvity's latest solution for specific typing of AD-associated APOE gene is likely to allow assessment of a patient's risk for adverse effects from new anti-amyloid therapy for Alzheimer's.
RVTY's continued focus on innovations and a strong product portfolio raise optimism about the stock.
RVTY's strong product portfolio raises optimism about the stock.
Investors interested in Medical Services stocks are likely familiar with Pediatrix Medical Group (MD) and Revvity (RVTY). But which of these two stocks presents investors with the better value opportunity right now?
Investors with an interest in Medical Services stocks have likely encountered both Pediatrix Medical Group (MD) and Revvity (RVTY). But which of these two stocks presents investors with the better value opportunity right now?
Revvity's (RVTY) second-quarter results showcase a decline in life sciences segmental revenues.
Revvity (RVTY) shares advanced Monday after the medical equipment maker formerly known as PerkinElmer posted better-than-expected results and boosted its profit guidance on higher demand for its diagnostic products.